Literature DB >> 3262123

Binding specificity of antiidiotypic autoantibodies to anti-DNA antibodies in humans.

T Sasaki1, T Muryoi, O Takai, E Tamate, H Saito, K Yoshinaga.   

Abstract

Human antiidiotypic antibodies to anti-DNA antibodies can be separated into at least two categories based on their binding to anti-DNA, antiidiotypic antibodies, and antigens. One type was found mainly in inactive stage of SLE. The antiidiotypic antibodies appear to be directed towards idiotype (Id) determinants in the antigen-binding sites of anti-DNA antibodies. Antibody from patient T.K. acted like a mirror image of anti-single-stranded DNA antibodies, O-81, as determined by a competitive inhibition RIA. Antibodies from patient S.U. also seemed to be Ab 2 beta and Ab 2 gamma to anti-double-stranded(ds) DNA antibodies, NE-1. Most of normal subjects, on the other hand, had antibodies that bound to the human monoclonal anti-ds DNA antibodies, NE-1, NE-13, 7F4, and O-81. The Id-anti-Id interaction was not inhibited by the addition of DNA. Thus, normal subjects had Ab2 alpha activity that recognizes Id determinants in the framework region common among anti-DNA antibodies, whereas antiidiotypic antibodies in most SLE sera appear to show Ab 2 beta and Ab 2 gamma activity. The results provide evidence that the Id network system regulates immunological tolerance to DNA in humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262123      PMCID: PMC303578          DOI: 10.1172/JCI113674

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Induction of T and B cell immunity by anti-idiotypic antibody.

Authors:  K Eichmann; K Rajewsky
Journal:  Eur J Immunol       Date:  1975-10       Impact factor: 5.532

2.  Shared idiotypes and restricted immunoglobulin variable region heavy chain genes characterize murine autoantibodies of various specificities.

Authors:  M Monestier; A Manheimer-Lory; B Bellon; C Painter; H Dang; N Talal; M Zanetti; R Schwartz; D Pisetsky; R Kuppers
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

3.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.

Authors:  E M Tan; P H Schur; R I Carr; H G Kunkel
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

4.  Specific purification of monoclonal anti-DNA antibodies from culture medium using a DNA-coupled Sepharose 4B affinity column.

Authors:  Y Kitagawa; T Sasaki
Journal:  J Immunol Methods       Date:  1987-01-26       Impact factor: 2.303

5.  Anti-thyroglobulin anti-idiotypic antibodies in sera of patients with Hashimoto's thyroiditis and Graves' disease.

Authors:  H M Sikorska
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

6.  Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.

Authors:  M A Agius; D P Richman
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

7.  Heterogeneity of anti-idiotypic antibodies to anti-DNA antibodies in humans.

Authors:  T Muryoi; T Sasaki; N Harata; O Takai; E Tamate; K Yoshinaga
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

8.  Idiotypy of rabbit antibodies. I. Comparison of idiotypy of antibodies against Salmonella typhi with that of antibodies against other bacteria in the same rabbits, or of antibodies against Salmonella typhi in various rabbits.

Authors:  J Oudin; M Michel
Journal:  J Exp Med       Date:  1969-09-01       Impact factor: 14.307

9.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

10.  Parallel sets of autoantibodies in MRL-lpr/lpr mice. An anti-DNA, anti-SmRNP, anti-gp70 network.

Authors:  P Migliorini; B Ardman; J Kaburaki; R S Schwartz
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.